Key facts
| Recalling firm | Abbott Molecular, Inc. |
|---|---|
| Manufacturer | Not disclosed in the FDA record. |
| Brand name | Not disclosed in the FDA record. |
| Product description | Alinity m Resp-4-Plex Amplification (AMP) Kit (CE), List Number 09N79-090, a multiplex real-time reverse transcription (RT) polymerase chain reaction (PCR) test intended for the qualitative detection and differentiation of RNA from influenza A virus (flu A), influenza B virus (flu B), Respiratory Syncytial Virus (RSV), and SARS-CoV-2 in nasopharyngeal (NP) swab specimens collected by a healthcare provider, from individuals with signs and symptoms of respiratory tract infection |
| Classification | Class II |
| Recall number | Z-1748-2025 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | There were reports of an increase in reactive negative controls and false positive results. |
What this classification means
A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Alinity m Resp-4-Plex Amplification (AMP) Kit (CE), List Number 09N79-090, a multiplex real-time reverse transcription (RT) polymerase chain reaction (PCR) test intended for the qualitative detection and differentiation of RNA from influenza A virus (flu A), influenza B virus (flu B), Respiratory Syncytial Virus (RSV), and SARS-CoV-2 in nasopharyngeal (NP) swab specimens collected by a healthcare provider, from individuals with signs and symptoms of respiratory tract infection should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Abbott Molecular, Inc.. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Abbott Molecular, Inc. should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Abbott Molecular, Inc. directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
Abbott Molecular, Inc.’s FDA history
Argus HQ has recorded 12 total FDA actions tied to Abbott Molecular, Inc.: 0 warning letters, 12 recalls, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- Has Abbott Molecular, Inc. had other FDA recalls or enforcement actions?
- Yes. Argus HQ has recorded 12 total FDA actions tied to Abbott Molecular, Inc., including 12 recalls and 0 warning letters.
- What is the FDA recall number for this event?
- FDA recall number Z-1748-2025.
- What is the current status of this recall?
- Status as recorded by FDA: Ongoing.
- Where can I verify this recall directly with FDA?
- The verbatim FDA record is the source of truth for every recall Argus HQ tracks — always confirm against fda.gov before acting.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Abbott Molecular, Inc.- Recall: Abbott Molecular, Inc. — Class II recall: Alinity m Resp-4-Plex AMP Kit, List Number 09N79-096, a multiplex real-time reve… →
- Recall: Abbott Molecular, Inc. — Class II recall: The Alinity m System is designed to automate the steps for nucleic acid testing.… →
- Recall: Abbott Molecular, Inc. — Class II recall: Abbott Alinity m HPV AMP Kit, used with the Alinity m System, product codes: a)… →
- Recall: Abbott Molecular, Inc. — Class II recall: Abbott Alinity m STI AMP Kit, used with the Alinity m System, product codes: a)… →
- Recall: Abbott Molecular, Inc. — Class II recall: Alinity m System, Part Number: 08N53-002 →
- Recall: Abbott Molecular, Inc. — Class III recall: In-vitro diagnostic kits: (1) Abbott Vysis MDM2 / CEP 12 FISH Probe Kit, REF… →
- Recall: Abbott Molecular, Inc. — Class III recall: In-vitro diagnostic kits: (1) Abbott Vysis LSI ATM (11q22.3) SpectrmOrange Pr… →
- Recall: Abbott Molecular, Inc. — Class III recall: Wash station: M1000 Wash Station Assembly & DITI Slide, REF 04J72-28* (*This pa… →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2025). Recall Record: Class II Recall: Alinity m Resp-4-Plex Amplification (AMP) Kit (CE), List… by Abbott Molecular, Inc.. Digital Empire LLC. Retrieved from https://argushq.ai/recall/abbott-molecular-z-1748-2025-2025-05-21
"Recall Record: Class II Recall: Alinity m Resp-4-Plex Amplification (AMP) Kit (CE), List… by Abbott Molecular, Inc.." Argus HQ Research, Digital Empire LLC, 2025, argushq.ai/recall/abbott-molecular-z-1748-2025-2025-05-21.
Argus HQ Research. "Recall Record: Class II Recall: Alinity m Resp-4-Plex Amplification (AMP) Kit (CE), List… by Abbott Molecular, Inc.." Digital Empire LLC. Accessed July 17, 2026. https://argushq.ai/recall/abbott-molecular-z-1748-2025-2025-05-21.
@misc{argushq_argushq_ai_recall_abbott_molecular_z_1748_2025_2025_05_21_2025,
title = {Recall Record: Class II Recall: Alinity m Resp-4-Plex Amplification (AMP) Kit (CE), List… by Abbott Molecular, Inc.},
author = {{Argus HQ Research}},
year = {2025},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/recall/abbott-molecular-z-1748-2025-2025-05-21},
note = {Accessed: July 17, 2026}
}Source: FDA.gov — Recalls ↗

